After More Than a Decade: Can We Now Enhance Treatment of Patients With LA SCCHN?

•Download as PPT, PDF•

0 likes•21 views

Kevin Harrington, PhD, FRCR, FRCP, Ezra Cohen, MD, FRCPSC, FASCO, and Barbara Burtness, MD, discuss locally advanced squamous cell carcinoma of head and neck (LA SCCHN) in this CME activity titled "After More Than a Decade: Can We Now Enhance Treatment of Patients With LA SCCHN?" For the full presentation, please visit us at www.peervoice.com/FQG870.

After More Than a Decade: Can We Now Enhance Treatment of Patients With LA SCCHN?

Overall life span (LS) was 1671.7±1721.6 days and cumulative 5YS reached 62.4%, 10 years – 50.4%, 20 years – 44.6%. 94 LCP lived more than 5 years without cancer (LS=2958.6±1723.6 days), 22 – more than 10 years (LS=5571±1841.8 days). 67 LCP died because of LC (LS=471.9±344 days). AT significantly improved 5YS (68% vs. 53.7%) (P=0.028 by log-rank test). Cox modeling displayed that 5YS of LCP significantly depended on: N0-N12, T3-4, blood cell circuit, cell ratio factors (ratio between cancer cells-CC and blood cells subpopulations), LC cell dynamics, recalcification time, heparin tolerance, prothrombin index, protein, AT, procedure type (P=0.000-0.031). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and N0-12 (rank=1), thrombocytes/CC (rank=2), segmented neutrophils/CC (3), eosinophils/CC (4), erythrocytes/CC (5), healthy cells/CC (6), lymphocytes/CC (7), stick neutrophils/CC (8), leucocytes/CC (9), monocytes/CC (10). Correct prediction of 5YS was 100% by neural networks computing (error=0.000; area under ROC curve=1.0).

Recently uploaded

micro teaching on communication m.sc nursing.pdf

Anurag Sharma

Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...

Oleg Kshivets

263778731218 Abortion Clinic /Pills In Harare ,

sisternakatoto

263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/

Journal Article Review on Rasamanikya

Dr. Jyothirmai Paindla

Rasamanikya is a excellent preparation in the field of Rasashastra, it is used in various Kushtha Roga, Shwasa, Vicharchika, Bhagandara, Vatarakta, and Phiranga Roga. In this article Preparation& Comparative analytical profile for both Formulationon i.e Rasamanikya prepared by Kushmanda swarasa & Churnodhaka Shodita Haratala. The study aims to provide insights into the comparative efficacy and analytical aspects of these formulations for enhanced therapeutic outcomes.

Chapter 11 Nutrition and Chronic Diseases.pptx

Earlene McNair

Netter's Atlas of Human Anatomy 7.ed.pdf

BrissaOrtiz3

Cervical & Brachial Plexus By Dr. RIG.pptx

Dr. Rabia Inam Gandapore

Aortic Association CBL Pilot April 19 – 20 Bern

suvadeepdas911

NVBDCP.pptx Nation vector borne disease control program

Sapna Thakur

A Classical Text Review on Basavarajeeyam

Dr. Jyothirmai Paindla

Sex determination from mandible pelvis and skull

ShashankRoodkee

Antimicrobial stewardship to prevent antimicrobial resistance

GovindRankawat1

India is among the nations with the highest burden of bacterial infections. India is one of the largest consumers of antibiotics worldwide. India carries one of the largest burdens of drug‑resistant pathogens worldwide. Highest burden of multidrug‑resistant tuberculosis, Alarmingly high resistance among Gram‑negative and Gram‑positive bacteria even to newer antimicrobials such as carbapenems. NDM‑1 ( New Delhi Metallo Beta lactamase 1, an enzyme which inactivates majority of Beta lactam antibiotics including carbapenems) was reported in 2008

Light House Retreats: Plant Medicine Retreat Europe

Lighthouse Retreat

ARTHROLOGY PPT NCISM SYLLABUS AYURVEDA STUDENTS

Dr. Vinay Pareek

Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists

Saeid Safari

Adv. biopharm. APPLICATION OF PHARMACOKINETICS : TARGETED DRUG DELIVERY SYSTEMS

AkankshaAshtankar

THERAPEUTIC ANTISENSE MOLECULES .pptx

70KRISHPATEL

Integrating Ayurveda into Parkinson’s Management: A Holistic Approach

Ayurveda ForAll

DISSERTATION on NEW DRUG DISCOVERY AND DEVELOPMENT STAGES OF DRUG DISCOVERY

NEHA GUPTA

The process of drug discovery and development is a complex and multi-step endeavor aimed at bringing new pharmaceutical drugs to market. It begins with identifying and validating a biological target, such as a protein, gene, or RNA, that is associated with a disease. This step involves understanding the target's role in the disease and confirming that modulating it can have therapeutic effects. The next stage, hit identification, employs high-throughput screening (HTS) and other methods to find compounds that interact with the target. Computational techniques may also be used to identify potential hits from large compound libraries. Following hit identification, the hits are optimized to improve their efficacy, selectivity, and pharmacokinetic properties, resulting in lead compounds. These leads undergo further refinement to enhance their potency, reduce toxicity, and improve drug-like characteristics, creating drug candidates suitable for preclinical testing. In the preclinical development phase, drug candidates are tested in vitro (in cell cultures) and in vivo (in animal models) to evaluate their safety, efficacy, pharmacokinetics, and pharmacodynamics. Toxicology studies are conducted to assess potential risks. Before clinical trials can begin, an Investigational New Drug (IND) application must be submitted to regulatory authorities. This application includes data from preclinical studies and plans for clinical trials. Clinical development involves human trials in three phases: Phase I tests the drug's safety and dosage in a small group of healthy volunteers, Phase II assesses the drug's efficacy and side effects in a larger group of patients with the target disease, and Phase III confirms the drug's efficacy and monitors adverse reactions in a large population, often compared to existing treatments. After successful clinical trials, a New Drug Application (NDA) is submitted to regulatory authorities for approval, including all data from preclinical and clinical studies, as well as proposed labeling and manufacturing information. Regulatory authorities then review the NDA to ensure the drug is safe, effective, and of high quality, potentially requiring additional studies. Finally, after a drug is approved and marketed, it undergoes post-marketing surveillance, which includes continuous monitoring for long-term safety and effectiveness, pharmacovigilance, and reporting of any adverse effects.

Top Effective Soaps for Fungal Skin Infections in India

SwisschemDerma

Recently uploaded (20)